Tag: yield

SUGAR LAND, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- CVR Energy, Inc. (NYSE: CVI, “CVR Energy” or the “Company”) today announced second quarter 2025 net loss attributable to CVR Energy stockholders of $114 million, or $1.14 per diluted share, compared to second quarter 2024 net income attributable to CVR Energy stockholders of $21 million, or 21 cents per diluted share. Adjusted loss for the second quarter of 2025 was 23 cents per diluted share, compared to adjusted earnings per diluted share of 9 cents in the second quarter of 2024. Net loss for the second quarter of 2025 was $90 million, compared to net income of $38 million in the second quarter of 2024. Second quarter 2025 EBITDA loss was $24 million, compared to second quarter 2024 EBITDA of $103 million. Adjusted EBITDA for the second quarter of 2025 was $99 million, compared to adjusted EBITDA of $87 million in the second quarter of 2024.

Continued Top-line Momentum Drives Exceptional Earnings Growth

Net Income per Diluted Share of $10.02 for the Quarter, inclusive of Income from Discontinued Operations

TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Ninepoint Partners LP (“Ninepoint Partners”) today announced the final July 2025 cash distribution for the Ninepoint Cash Management Fund - ETF Series. The record date for the distribution is July 31, 2025. This distribution is payable on August 8, 2025.

PRESS RELEASE

COMMUNIQUÉ DE PRESSE

FORESIGHT VENTURES VCT PLC
LEI: 213800R88MRC4Y3OIW86
29 July 2025

WEST PALM BEACH, FL, July 30, 2025 (GLOBE NEWSWIRE) -- LXP Industrial Trust (“LXP”) (NYSE:LXP), a real estate investment trust focused on Class A warehouse and distribution real estate investments, today announced results for the quarter ended June 30, 2025.

Please find below Aedifica’s 2025 half year financial report.

New Non-Stimulant Supplement Aims to Complement Overnight Wellness Routines with Polyamine-Aligned Botanical Support

22nd Century VLN^® products are the only combustible cigarettes authorized by the FDA as a reduced nicotine content product that comply with the FDA proposed rule